ChemoCentryx, Inc.
850 Maude Avenue
Mountain View
California
94043
United States
Tel: 650-210-2900
Fax: 650-210-2910
Website: http://www.chemocentryx.com/
Email: info@chemocentryx.com
About ChemoCentryx, Inc.
"People Deserve Better Medicine and not just a longer life---a better life."
Located in the heart of the Silicon Valley, ChemoCentyx is a biotechnology company that focuses on chronic kidney diseases, immuno-oncology, and other autoimmune and inflammatory diseases.
Our vision can only be accomplished through talented people who share our culture and values.
We have created a corporate culture of scientific innovation, placing emphasis on hard work, honesty, and industry-leading technology in a fun, team-oriented atmosphere. We treat each other with respect at all times. We expect employees to add value as individuals and as team members. We work hard to nurture this environment.
As a late clinical development stage company, we are focused on a pipeline that discovers, develops and commercializes orally-administered therapeutics.
"ChemoCentryx: Great Science, Great Medicine"
223 articles with ChemoCentryx, Inc.
-
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
5/18/2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that a poster will be presented at the Society for Investigative Dermatology (SID) 2022 Annual Meeting, to be held May 18-21, 2022 in Portland, Oregon, that highlights unique immunological profiles of the subdermal tunnels in hidradenitis suppurativa, and how these profiles are differentiated with the stage of disease severity.
-
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
5/16/2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET.
-
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
5/11/2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS ® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis.
-
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
5/5/2022
ChemoCentryx, Inc., announced financial results for the first quarter ended March 31, 2022 and provided an overview of recent corporate highlights.
-
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
4/28/2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022.
-
The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
-
ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022
4/13/2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase I clinical study of CCX559 during a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022.
-
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
3/1/2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided an overview of recent corporate highlights.
-
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022
2/23/2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022.
-
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2/9/2022
ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16th at 5:00 p.m. Eastern Time.
-
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis
1/19/2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS ® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis.
-
ChemoCentryx to Present at Two Upcoming Investor Conferences - Jan 04, 2022
1/4/2022
ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences.
-
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
11/12/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS
-
ChemoCentryx to Participate in Two Upcoming Investor Conferences - Nov 10, 2021
11/10/2021
ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences.
-
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
11/9/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced financial results for the third quarter ended September 30, 2021 and provided an overview of recent corporate highlights.
-
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)
11/4/2021
ChemoCentryx, Inc., announced the abstracts accepted for presentation and publication as part of the annual meetings of the American Society of Nephrology Kidney Week 2021 and American College of Rheumatology Convergence 2021, taking place November 2-7, 2021 and November 3-9, 2021, respectively.
-
ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021
11/2/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021.
-
ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer
10/11/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer.
-
The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for adults with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis).
-
ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis
10/8/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis